Evidence map›Paper›PMID 32499611›Full record

ArticleScientific reports2020

Vasopressin receptor 2 mutations in the nephrogenic syndrome of inappropriate antidiuresis show different mechanisms of constitutive activation for G protein coupled receptors.

Vanessa Vezzi, Caterina Ambrosio, Maria Cristina Grò, Paola Molinari, Gökçe Süral, Tommaso Costa, H Ongun Onaran, Susanna Cotecchia

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Vanessa VezziIstituto Superiore di Sanitá, National Center for Drug Research and Evaluation, Rome, Italy.
Caterina AmbrosioIstituto Superiore di Sanitá, National Center for Drug Research and Evaluation, Rome, Italy.
Maria Cristina GròIstituto Superiore di Sanitá, National Center for Drug Research and Evaluation, Rome, Italy.
Paola MolinariIstituto Superiore di Sanitá, National Center for Drug Research and Evaluation, Rome, Italy.
Gökçe SüralAnkara University, Faculty of Medicine, Department of Pharmacology, Molecular biology and Technology development unit, Sıhhiye, Ankara, Turkey.
Tommaso CostaIstituto Superiore di Sanitá, National Center for Drug Research and Evaluation, Rome, Italy.
H Ongun OnaranAnkara University, Faculty of Medicine, Department of Pharmacology, Molecular biology and Technology development unit, Sıhhiye, Ankara, Turkey.
Susanna CotecchiaDepartment of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, 70125, Bari, Italy. susanna.cotecchia@uniba.it.
Istituto Superiore di Sanità · ITAnkara University · TRUniversity of Bari Aldo Moro · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vasopressin receptor 2 (V2R) mutations causing the nephrogenic syndrome of inappropriate antidiuresis (NSIAD) can generate two constitutively active receptor phenotypes. One type results from residue substitutions in several V2R domains and is sensitive to vaptan inverse agonists. The other is only caused by Arg 137 replacements and is vaptan resistant. We compared constitutive and agonist-driven interactions of the vaptan-sensitive F229V and vaptan-resistant R137C/L V2R mutations with β-arrestin 1, β-arrestin 2, and Gαs, using null fibroblasts reconstituted with individual versions of the ablated transduction protein genes. F229V displayed very high level of constitutive activation for Gs but not for β-arrestins, and enhanced or normal responsiveness to agonists and inverse agonists. In contrast, R137C/L mutants exhibited maximal levels of constitutive activation for βarrestin 2 and Gs, minimal levels for β-arrestin 1, but a sharp decline of ligands sensitivity at all transducer interactions. The enhanced constitutive activity and reduced ligand sensitivity of R137 mutants on cAMP signaling persisted in cells lacking β-arrestins, indicating that these are intrinsic molecular properties of the mutations, not the consequence of altered receptor trafficking. The results suggest that the two groups of NSIAD mutations represent two distinct molecular mechanisms of constitutive activation in GPCRs.

Indexed as

Mutationbeta-Arrestin 1beta-Arrestin 2Cell LineFemaleGenetic Diseases, X-LinkedHumansInappropriate ADH SyndromeMaleProtein DomainsReceptors, G-Protein-CoupledReceptors, VasopressinARRB1 protein, humanbeta-Arrestin 1beta-Arrestin 2Receptors, G-Protein-CoupledReceptors, Vasopressin

Identifiers

PMID32499611
PMCPMC7272623
OpenAlexW3033655377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.